@ionispharma Ionis

Ionis posts on X about $ions, has been, we are, ceo the most. They currently have [-----] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

• [--] Month [-----] -23%
• [--] Months [------] +68%
• [--] Year [------] +592%

Mentions: [--] #

• [--] Months [--] +328%
• [--] Year [--] +520%

Followers: [-----] #

• [--] Month [-----] -0.19%
• [--] Months [-----] +1.80%
• [--] Year [-----] +3.10%

CreatorRank: [---------] #

Social Influence

Social category influence finance 7.61% countries 2.17% financial services 1.09% stocks 1.09% exchanges 1.09%

Social topic influence $ions #5, has been 5.43%, we are 4.35%, ceo 4.35%, tune 3.26%, live on 3.26%, watch 3.26%, $4578t 3.26%, $4768t 3.26%, science 3.26%

Top accounts mentioned or mentioned by @balancingacttv @lifetimetv @angelman @cureangelman @unc @alnylam @harvardstemcell @childneurosoc @sonichedgefund @bostonchildrens @naturebiotech @nature @natrevdrugdisc @citeline @sdbusinesss @otsociety @balancingacttvs @acaai @bpmonia @natureportfolio

Top assets mentioned Ionis Pharmaceuticals, Inc. Common Stock (IONS) Brett (BRETT) sETH (SETH) April (APRIL)

Top Social Posts

Top posts by engagements in the last [--] hours

"Save the date for our Q4 and full year [----] earnings webcast. Register now and tune in live on February [--] at 11:30 am ET: $IONS https://bit.ly/4qtnIUo https://bit.ly/4qtnIUo"
X Link 2026-02-11T14:20Z [----] followers, [---] engagements

"On International Angelman Day we recognize the strength resilience and joy of this community. To learn more about #Angelmansyndrome watch our @balancingacttv Behind the Mystery of Angelman syndrome episode on our website: $IONS https://bit.ly/4afZYhY https://bit.ly/4afZYhY"
X Link 2026-02-15T14:00Z [----] followers, [---] engagements

"Today we announced an expanded license agreement with Otsuka Pharmaceutical under which they will support commercialization in Asia Pacific for our investigational prophylactic medicine for hereditary angioedema (#HAE). Read more: $IONS https://ir.ionis.com/news-releases/news-release-details/ionis-announces-expanded-licensing-agreement-otsuka-asia-pacific https://ir.ionis.com/news-releases/news-release-details/ionis-announces-expanded-licensing-agreement-otsuka-asia-pacific"
X Link 2024-06-18T11:02Z [----] followers, [----] engagements

"Welook forward to hostinginvestors & analysts forIonis Innovation Day on October 7th. The agenda will feature presentations from our leadership team & a key thought leader inthe treatment of sHTG FCS & lipid disorders. Learn more & register: $IONS https://ir.ionis.com/news-releases/news-release-details/ionis-host-investors-and-analysts-innovation-day-2025 https://ir.ionis.com/news-releases/news-release-details/ionis-host-investors-and-analysts-innovation-day-2025"
X Link 2025-09-16T19:49Z [----] followers, [---] engagements

"Severe hypertriglyceridemia (sHTG) occurs when triglycerides exceed [---] mg/dL posing risks such as acute pancreatitis and cardiovascular disease. HCPs learn more: https://tgaware.com/associated-risks-shtg https://tgaware.com/associated-risks-shtg"
X Link 2025-09-17T18:02Z [----] followers, [---] engagements

"Today we announced that Ionis and Sobis treatment for familial chylomicronemia syndrome (FCS) has been approved in the European Union (EU). Read more about the news: $IONS https://ir.ionis.com/news-releases/news-release-details/tryngolzar-olezarsen-approved-european-union-familial https://ir.ionis.com/news-releases/news-release-details/tryngolzar-olezarsen-approved-european-union-familial"
X Link 2025-09-19T11:01Z [----] followers, [----] engagements

"We are excited to announce positive topline results from our pivotal study of zilganersen an investigational RNA-targeted medicine in development for the treatment of #Alexanderdisease (AxD) a rare progressive #neurological condition. Read more: $IONS https://ir.ionis.com/news-releases/news-release-details/ionis-announces-positive-topline-results-pivotal-study https://ir.ionis.com/news-releases/news-release-details/ionis-announces-positive-topline-results-pivotal-study"
X Link 2025-09-22T11:01Z [----] followers, [----] engagements

"Academics researching nucleic acids dont miss this opportunity to share your cutting-edge insights in RNA-targeted technology. Present your research in front of the biggest names in RNA medicine network and meet new peers. Poster + oral presentation spaces for abstracts still available https://t.co/RIGVMQVmZS @Alnylam @ionispharma @harvardstemcell @BostonChildrens @NatureBiotech @Nature @NatRevDrugDisc https://t.co/7HE5KcJZRJ Present your research in front of the biggest names in RNA medicine network and meet new peers. Poster + oral presentation spaces for abstracts still available"
X Link 2025-09-24T16:47Z [----] followers, [---] engagements

"Were thrilled our medicine for familial chylomicronemia syndrome (FCS) has been shortlisted for the @Citeline [----] #ScripAwards in the Best New Drug Award category. We are honored to be recognized #LivingwithFCS #RareDisease https://www.citeline.com/en/awards/scripawards https://www.citeline.com/en/awards/scripawards"
X Link 2025-09-25T19:02Z [----] followers, [---] engagements

"Wereproud to share that Ionis ranked #6on @SDbusinesss [----] Best Places to Work list Our second consecutive year being recognized and our first year breaking into the Top 10thanks to every Ion who shapesour culture. More: #BestPlacesToWork https://ionis.com/newsroom/people-impact/best-place-to-work-2025 https://ionis.com/newsroom/people-impact/best-place-to-work-2025"
X Link 2025-10-01T14:01Z [----] followers, [---] engagements

"Tomorrow $IONS will be hosting investors and analysts for Innovation Day. Presentations will highlight the companys acceleration of growth. Click here to register: https://event.webcasts.com/starthere.jspei=1723740&tp_key=9a11e179ac https://event.webcasts.com/starthere.jspei=1723740&tp_key=9a11e179ac"
X Link 2025-10-06T17:36Z [----] followers, [---] engagements

"$IONS is hosting investors and analysts for Innovation Day. Presentations will feature our high-value pipeline fueled by groundbreaking technology strong trajectory of ongoing & near-term launches & clear path to sustained positive cash flow. https://ir.ionis.com/news-releases/news-release-details/ionis-showcases-transformational-medicines-and-industry-leading https://ir.ionis.com/news-releases/news-release-details/ionis-showcases-transformational-medicines-and-industry-leading"
X Link 2025-10-07T11:02Z [----] followers, [----] engagements

"Headed to the [----] @ChildNeuroSoc Annual Meeting (#CNSAM) Stop by booth [---] to meet some of our amazing team members and learn about our latest advancements in #neurology. $IONS"
X Link 2025-10-08T20:09Z [----] followers, [---] engagements

"Save the date for our Q3 [----] earnings webcast. Register now and tune in live on October [--] at 11:30 am ET: https://ir.ionis.com/news-releases/news-release-details/ionis-hold-third-quarter-2025-financial-results-webcast https://ir.ionis.com/news-releases/news-release-details/ionis-hold-third-quarter-2025-financial-results-webcast"
X Link 2025-10-16T12:49Z [----] followers, [---] engagements

"Today Brett Monia founding scientist and CEO of Ionis was honored with the [----] Lifetime Achievement Award from the @OTSociety for his contributions to the discovery and development of oligonucleotide therapeutics. Learn more: http://ionis.com/newsroom/people-impact/ionis-ceo-brett-monia-phd-receives-2025-lifetime-achievement-award-oligonucleotide http://ionis.com/newsroom/people-impact/ionis-ceo-brett-monia-phd-receives-2025-lifetime-achievement-award-oligonucleotide"
X Link 2025-10-21T12:16Z [----] followers, [---] engagements

"Data from the landmark CORE and CORE2 pivotal studies for our treatment for severe hypertriglyceridemia (sHTG) will be a late-breaking presentation at #AHA25. Join us for an investor webcast afterwards on Nov. [--]. More details here: $IONS https://ir.ionis.com/news-releases/news-release-details/detailed-data-landmark-core-and-core2-pivotal-studies-olezarsen https://ir.ionis.com/news-releases/news-release-details/detailed-data-landmark-core-and-core2-pivotal-studies-olezarsen"
X Link 2025-10-27T11:02Z [----] followers, [---] engagements

"Today we reported Q3 [----] financial results. Read more about our updates and tune in live to the webcast today at 11:30 AM ET to hear our third quarter highlights: $IONS http://bit.ly/4hyHICd http://bit.ly/4hyHICd"
X Link 2025-10-29T11:01Z [----] followers, [---] engagements

"Were excited to announce @BalancingActTVs Behind the Mystery of Angelman syndrome episode airing on @LifetimeTV a look into the lives of families advocates & experts impacted by this rare condition. Tune in Nov. [--] & [--] at 7:30 a.m. ET/PT to see these stories come to life"
X Link 2025-10-30T14:08Z [----] followers, [---] engagements

"High fasting triglyceride levels [---] mg/dL are an indicator of severe hypertriglyceridemia which may lead to health problems such as acute pancreatitis and atherosclerotic cardiovascular disease. HCPs learn more: https://bit.ly/4qNJtzZ https://bit.ly/4qNJtzZ"
X Link 2025-11-03T20:05Z [----] followers, [---] engagements

"Were at the @ACAAI Annual Scientific Meeting presenting new long-term data from the OASISplus study in hereditary angioedema (#HAE). Learn more: #RareDisease #ACAAI2025 https://bit.ly/47Z3r3c https://bit.ly/47Z3r3c"
X Link 2025-11-06T13:03Z [----] followers, [---] engagements

"Ionis is at #AHA25 We are looking forward to connecting with healthcare providers to discuss the unmet need and risks associated with severe hypertriglyceridemia (sHTG). Visit our disease education booth #4325 to learn more"
X Link 2025-11-07T16:03Z [----] followers, [---] engagements

"$IONS is hosting an investor webcast on 11/8 to discuss the results from the CORE and CORE2 pivotal studies for our treatment for severe hypertriglyceridemia (sHTG). Sign up here: #AHA25 https://bit.ly/4nETUCZ https://bit.ly/4nETUCZ"
X Link 2025-11-07T19:00Z [----] followers, [---] engagements

"We are excited to announce groundbreaking data from our pivotal studies for severe hypertriglyceridemia (sHTG) at #AHA25. sHTG is defined by triglycerides [---] mg/dL & characterized by increased risk of acute pancreatitis & other morbidities. More: $IONS https://bit.ly/49rTcFZ https://bit.ly/49rTcFZ"
X Link 2025-11-08T14:50Z [----] followers, [----] engagements

"Today we announced groundbreaking results from our pivotal studies for severe hypertriglyceridemia (sHTG) at #AHA25. Read more: These data exemplify how we are turning groundbreaking science into meaningful medicines for patients. $IONS https://bit.ly/49rTcFZ https://bit.ly/49rTcFZ"
X Link 2025-11-08T19:00Z [----] followers, [----] engagements

"Tune in today at 12:45 pm ET where CEO @BPMonia will be presenting at #JPM2023 Join here: $IONS #Ionis #JPM23 http://ow.ly/SvoM50MnihH http://ow.ly/SvoM50MnihH"
X Link 2023-01-11T15:02Z [----] followers, [----] engagements

"$IONS Ionis reports fourth quarter and full year [----] financial results https://prn.to/41lLVkf https://prn.to/41lLVkf"
X Link 2023-02-22T12:01Z [----] followers, [---] engagements

"$IONS Ionis reports first quarter [----] financial results https://prn.to/40SmC84 https://prn.to/40SmC84"
X Link 2023-05-03T11:01Z [----] followers, [---] engagements

"$IONS Ionis announces proposed private placement of convertible notes https://prn.to/3Ng6kSU https://prn.to/3Ng6kSU"
X Link 2023-06-06T20:02Z [----] followers, [----] engagements

"Today we announced a new license agreement with Ono Pharmaceutical Co. Ltd for the exclusive global rights for our investigational RNA-targeted medicine for people living with polycythemia vera (PV). Read more about todays news: #raredisease https://ir.ionis.com/news-releases/news-release-details/ionis-and-ono-announce-global-license-agreement-sapablursen https://ir.ionis.com/news-releases/news-release-details/ionis-and-ono-announce-global-license-agreement-sapablursen"
X Link 2025-03-11T22:02Z [----] followers, [---] engagements

"Cardiometabolic diseases are among the most pressing health challenges reinforcing the importance of innovation & groundbreaking science to drive change. Learn about our ambition to transform lives for people affected by cardiometabolic disease: #AHA25 https://bit.ly/43QAxzO https://bit.ly/43QAxzO"
X Link 2025-11-10T18:18Z [----] followers, [---] engagements

"Our Ions were busy at #AHA25 this past weekend exchanging knowledge & advancing our scientific understanding of severe hypertriglyceridemia (sHTG). It was an inspiring & energizing weekend full of hope & progress. Thank you to all who joined us in New Orleans. See you next year"
X Link 2025-11-12T18:10Z [----] followers, [---] engagements

"Today the CHMP in the European Union voted to recommend the approval of Ionis and Otsuka Pharmaceutical Co. Ltd.s prophylactic treatment for hereditary angioedema (#HAE). Learn more about this exciting news: $IONS https://bit.ly/4oyIuC2 https://bit.ly/4oyIuC2"
X Link 2025-11-14T12:02Z [----] followers, [----] engagements

"Tune in tomorrow at 7:30 a.m. ET/PT to our @balancingacttv Behind the Mystery episode on @LifetimeTV to learn more about #AngelmanSyndrome a rare genetic neurological condition affecting [--] in [-----] people worldwide. #RareDisease @Angelman @CureAngelman @UNC"
X Link 2025-11-18T15:41Z [----] followers, [---] engagements

"Todays the day: Our @balancingacttv Behind the Mystery of Angelman syndrome episode airs on @LifetimeTV at 7:30 a.m. ET/PT. Tune in live or watch the episode on our website: #BehindtheMystery #RareDisease @Angelman @CureAngelman @UNC $IONS https://bit.ly/3XBWf77 https://bit.ly/3XBWf77"
X Link 2025-11-19T12:36Z [----] followers, [---] engagements

"Managing severe hypertriglyceridemia (sHTG) is complex given its overlap with conditions like diabetes. HCPs learn how managing triglycerides can help mitigate the risk of acute pancreatitis and atherosclerotic cardiovascular disease: https://bit.ly/4oaSDnr https://bit.ly/4oaSDnr"
X Link 2025-11-24T18:40Z [----] followers, [---] engagements

"ICYMI theres another chance to watch live: Our @balancingacttv Behind the Mystery of Angelman syndrome episode re-airs tomorrow on @LifetimeTV at 7:30 a.m. ET/PT. Hear from families caregivers & advocates: #BehindtheMystery @Angelman @CureAngelman @UNC https://bit.ly/3XBWf77 https://bit.ly/3XBWf77"
X Link 2025-11-26T16:47Z [----] followers, [---] engagements

"We are thrilled to share that we received U.S. FDA Breakthrough Therapy designation for our investigational treatment for severe hypertriglyceridemia (sHTG). More details here: https://bit.ly/4rw9vrB https://bit.ly/4rw9vrB"
X Link 2025-12-01T12:01Z [----] followers, [----] engagements

"We are excited to announce that we received U.S. FDA Breakthrough Therapy designation for our investigational treatment for Alexander disease (AxD). Read our release here: $IONS https://bit.ly/3KrpqH8 https://bit.ly/3KrpqH8"
X Link 2025-12-02T17:59Z [----] followers, [----] engagements

"Alongside @NaturePortfolio @Alnylam and @HarvardStemCell were excited to sponsorCracking the Code: Nucleic Acid Medicines Coming of Age this week an event bringing together academics and industry professionals to explore developments and challenges in nucleic acid medicines"
X Link 2025-12-09T17:59Z [----] followers, [---] engagements

"Severe hypertriglyceridemia (sHTG) occurs when triglycerides exceed [---] mg/dL posing risks such as acute pancreatitis and cardiovascular disease. HCPs learn more: https://bit.ly/45oFIaT https://bit.ly/45oFIaT"
X Link 2025-12-22T19:56Z [----] followers, [---] engagements

"The 44th Annual J.P. Morgan Healthcare Conference takes place next week in San Francisco. On Tuesday our CEO Brett Monia will present a company overview and preview [----] commercial regulatory and pipeline goals. #JPM2026 https://bit.ly/3Nh66NH https://bit.ly/3Nh66NH"
X Link 2026-01-06T20:28Z [----] followers, [---] engagements

"Today with our partner @GSK we announced positive topline results for an investigational medicine for the treatment of chronic hepatitis B (CHB). Learn more: https://bit.ly/4bkpvHw https://bit.ly/4bkpvHw"
X Link 2026-01-07T12:00Z [----] followers, [---] engagements

"Cardiometabolic diseases are among the most pressing health challenges reinforcing the importance of innovation & groundbreaking science to drive change. Learn about our ambition to transform lives for people affected by cardiometabolic disease: https://bit.ly/43QAxzO https://bit.ly/43QAxzO"
X Link 2026-01-08T20:02Z [----] followers, [---] engagements

"Join us Tuesday for a business update from our CEO Brett P. Monia PhD on [----] achievements and updates on key milestones expected in [----]. Learn more: $IONS #JPM2026 https://bit.ly/45HhtVB https://bit.ly/45HhtVB"
X Link 2026-01-12T12:02Z [----] followers, [---] engagements

"At #JPM26 we painted a bold picture of a catalyst-rich year ahead for Ionis. Curious about whats to come Hear from our CEO Brett P. Monia PhD about the upcoming year by the numbers: https://ionis.com/newsroom/defining-moments/ionis-jpm-2026-takeaways-breakthrough-therapies-driving-accelerating https://ionis.com/newsroom/defining-moments/ionis-jpm-2026-takeaways-breakthrough-therapies-driving-accelerating"
X Link 2026-01-16T17:56Z [----] followers, [---] engagements

"We are excited to announce that Ionis and Otsuka Pharmaceutical Co. Ltd.s prophylactic treatment for hereditary angioedema (#HAE) has been approved in Europe. Learn more: $IONS https://bit.ly/3LYkUk5 https://bit.ly/3LYkUk5"
X Link 2026-01-21T12:02Z [----] followers, [---] engagements

"High triglycerides associated with severe hypertriglyceridemia (sHTG) increase the risk for acute pancreatitis. In people with a history of acute pancreatitis the risk of future attacks is even greater. HCPs learn more: http://bit.ly/42SWlug http://bit.ly/42SWlug"
X Link 2026-02-03T16:39Z [----] followers, [---] engagements

"Were committed to developing treatment advances for patients with unmet medical needs such as dry Age-related Macular Degeneration (#dryAMD) a leading cause of #blindness that currently has no cure. Learn more about our partnership: $IONS http://ir.ionispharma.com/news-releases/news-release-details/ionis-enters-new-collaboration-partner-develop-ionis-fb-l-rx http://ir.ionispharma.com/news-releases/news-release-details/ionis-enters-new-collaboration-partner-develop-ionis-fb-l-rx"
X Link 2018-10-10T13:50Z [----] followers, [--] engagements

"Our CEO Dr. Stanley Crooke speaks to @sciam about the company's #antisense technology and our commitment to delivering life-saving medicines to patients. $IONS https://www.scientificamerican.com/custom-media/inside-view-the-remarkable-sense-of-antisense/ https://www.scientificamerican.com/custom-media/inside-view-the-remarkable-sense-of-antisense/"
X Link 2018-12-17T17:02Z [----] followers, [--] engagements

"One of our core values: Have Fun So today we kicked off the [----] #MLB season the right way. RT if you had a great #OpeningDay too"
X Link 2019-03-29T05:25Z [----] followers, [--] engagements

"$IONS $AKCA Great news for adults living with Familial Chylomicronaemia Syndrome in England @NICEComms issued a positive recommendation for the first and only therapy for #FCS to be available on the NHS in England. More: #RareDisease http://ow.ly/y3Ec50BuFHt http://ow.ly/y3Ec50BuFHt"
X Link 2020-09-18T13:41Z [----] followers, [--] engagements

"$IONS Ionis initiates Phase [--] clinical program of donidalorsen in patients with hereditary angioedema https://prn.to/3Fwq3a2 https://prn.to/3Fwq3a2"
X Link 2021-11-18T18:31Z [----] followers, [--] engagements

"$IONS Ionis initiates Phase [--] clinical program of donidalorsen in patients with hereditary angioedema #antisense http://ow.ly/832T50GRit8 http://ow.ly/832T50GRit8"
X Link 2021-11-18T19:19Z [----] followers, [--] engagements

"$IONS Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare genetic form of ALS https://prn.to/3J6G5e7 https://prn.to/3J6G5e7"
X Link 2022-07-26T11:31Z [----] followers, [--] engagements

"$IONS Ionis announces positive topline results from Phase 2b clinical study of fesomersen a potential novel anti-thrombotic treatment https://prn.to/3OU7QrD https://prn.to/3OU7QrD"
X Link 2022-07-28T11:05Z [----] followers, [--] engagements

"New exploratory cardiac endpoints data from the Phase [--] NEURO-TTRansform study of eplontersen an investigational treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) were presented at #HFSA2023. Learn more:"
X Link 2023-10-07T19:25Z [--] followers, [----] engagements

"Today we announced that the U.S. FDA has granted Fast Track designation to our investigational medicine for the treatment of #AlexanderDisease (AxD). Read more: #RareDisease $IONS https://ir.ionis.com/news-releases/news-release-details/zilganersen-granted-us-fda-fast-track-designation-people-living https://ir.ionis.com/news-releases/news-release-details/zilganersen-granted-us-fda-fast-track-designation-people-living"
X Link 2024-10-01T11:01Z [----] followers, [---] engagements

"Today we announced the pivotal Phase [--] study design for our investigational #AngelmanSyndrome (AS) medicine following alignment with the U.S. FDA. Read more: #RareDisease $IONS https://ir.ionis.com/news-releases/news-release-details/ionis-announces-pivotal-phase-3-trial-design-ion582-angelman https://ir.ionis.com/news-releases/news-release-details/ionis-announces-pivotal-phase-3-trial-design-ion582-angelman"
X Link 2024-11-06T12:15Z [----] followers, [---] engagements

"Attending the [----] @ChildNeuroSoc Annual Meeting (#CNSAM) Stop by booth [---] to meet members of our amazing team and learn about our latest advancements in #ChildNeurology. $IONS"
X Link 2024-11-13T16:34Z [----] followers, [---] engagements

"BREAKING NEWS: Were thrilled to share the U.S. FDA has approved TRYNGOLZA (olezarsen) cementing Ionis as a fully integrated commercial-stage biotech company. Read more: $IONS https://ir.ionis.com/news-releases/news-release-details/tryngolzatm-olezarsen-approved-us-first-ever-treatment-adults https://ir.ionis.com/news-releases/news-release-details/tryngolzatm-olezarsen-approved-us-first-ever-treatment-adults"
X Link 2024-12-19T23:30Z [----] followers, [----] engagements

"Ionis will host an investor webcast to discuss the U.S. FDA approval of our medicine for the treatment of adults with familial chylomicronemia syndrome (FCS) as an adjunct to diet. Read more and access a link to the webcast here: $IONS https://app.webinar.net/lRgdAxXAmz5 https://app.webinar.net/lRgdAxXAmz5"
X Link 2024-12-19T23:35Z [----] followers, [---] engagements

"The FDA approval of our breakthrough treatment the first and only medicine in the U.S. for adults with familial chylomicronemia syndrome (FCS) as an adjunct to diet is an important milestone for the FCS community. Watch this video from our CEO Brett Monia to learn more"
X Link 2024-12-20T00:40Z [----] followers, [----] engagements

"ICYMI: The U.S. FDA approved our treatment for adults with familial chylomicronemia syndrome (FCS) as an adjunct to diet the first and only medicine for FCS in the U.S. Seth Baum shares what this means for the community. Learn more: $IONS https://ir.ionis.com/news-releases/news-release-details/tryngolzatm-olezarsen-approved-us-first-ever-treatment-adults https://ir.ionis.com/news-releases/news-release-details/tryngolzatm-olezarsen-approved-us-first-ever-treatment-adults"
X Link 2024-12-23T16:39Z [----] followers, [---] engagements

"Looking forward to gathering in San Francisco to discuss the latest innovations in healthcare at the J.P. MorganHealthcare Conference. Our CEO Brett Monia will preview commercial regulatory and pipeline milestones for Ionis in [----]. #JPM2025 $IONS https://ir.ionis.com/events https://ir.ionis.com/events"
X Link 2025-01-08T22:32Z [----] followers, [---] engagements

"Join Ionis CEO Brett Monia today at #JPM25 for a business update covering our significant progress in [----] and a preview of the commercial regulatory and pipeline milestones ahead for [----]. $IONS https://ir.ionis.com/events https://ir.ionis.com/events"
X Link 2025-01-15T14:54Z [----] followers, [---] engagements

"Ionis CEO Brett Monia PhD spoke with @BiotechTVHQ at #JPM25 providing details about the companys new chapter as a fully integrated commercial-stage biotech company. Watch his video interview & learn more about whats to come for Ionis in 2025: $IONS https://www.biotechtv.com/post/ionis-pharmaceuticals-january-15-2025 https://www.biotechtv.com/post/ionis-pharmaceuticals-january-15-2025"
X Link 2025-01-17T17:57Z [----] followers, [---] engagements

"The European Commission has approved Ionis and AstraZenecas medicine for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage [--] or stage [--] polyneuropathy. Read more: #raredisease $IONS https://ir.ionis.com/news-releases/news-release-details/wainzua-eplontersen-approved-eu-treatment-hereditary https://ir.ionis.com/news-releases/news-release-details/wainzua-eplontersen-approved-eu-treatment-hereditary"
X Link 2025-03-10T11:01Z [----] followers, [---] engagements

"Today our CEO Brett Monia rang the Nasdaq Opening Bell celebrating our recent FDA approval for the treatment of FCS - our first independent medicine Today is possible because of the dedication of our Ions & partners and the resilience of the patients we serve $IONS"
X Link 2025-03-24T15:44Z [----] followers, [----] engagements

"Today we announced an expanded partnership with Sobi granting them exclusive commercialization rights in countries outside the U.S. Canada and China for olezarsen. Read more about todays news: #raredisease $IONS https://ir.ionis.com/news-releases/news-release-details/ionis-expands-partnership-sobi-include-olezarsen https://ir.ionis.com/news-releases/news-release-details/ionis-expands-partnership-sobi-include-olezarsen"
X Link 2025-03-26T11:03Z [----] followers, [---] engagements

"Calling all HCPs attending #AANAM Stop by booth [---] to meet members of our incredible Ionis team and learn about our latest advancements in #neurology. For more information on our important work in this space visit: @AANmember $IONS https://neurology.ionis.com/ https://neurology.ionis.com/"
X Link 2025-04-07T18:25Z [----] followers, [---] engagements

"Replay now available: Expert panel of key thought leaders in lipidology cardiology & endocrinology discussed the risks clinical presentation & significant unmet medical needs associated with severe hypertriglyceridemia (sHTG) $IONS https://ir.ionis.com/events/event-details/expert-panel-discussion-shtg https://ir.ionis.com/events/event-details/expert-panel-discussion-shtg"
X Link 2025-04-16T15:46Z [----] followers, [----] engagements

"Save the date for our Q1 [----] earnings webcast. Register now and tune in live on April [--] at 11:30 am ET: $IONS https://ir.ionis.com/news-releases/news-release-details/ionis-hold-first-quarter-2025-financial-results-webcast https://ir.ionis.com/news-releases/news-release-details/ionis-hold-first-quarter-2025-financial-results-webcast"
X Link 2025-04-23T13:33Z [----] followers, [---] engagements

"Today we reported Q1 [----] financial results. Read more about our updates and tune in live to the webcast today at 11:30 AM ET to hear our first quarter highlights: $IONS https://ir.ionis.com/news-releases/news-release-details/ionis-reports-first-quarter-2025-financial-results https://ir.ionis.com/news-releases/news-release-details/ionis-reports-first-quarter-2025-financial-results"
X Link 2025-04-30T11:02Z [----] followers, [---] engagements

"Were pleased to announce positive topline results from our Essence study evaluating olezarsen in people with moderately elevated triglycerides. Read more: $IONS https://ir.ionis.com/news-releases/news-release-details/ionis-announces-positive-topline-results-essence-study-olezarsen https://ir.ionis.com/news-releases/news-release-details/ionis-announces-positive-topline-results-essence-study-olezarsen"
X Link 2025-05-19T11:02Z [----] followers, [----] engagements

"Today we announced that the first participant has been dosed in the global Phase [--] REVEAL trial evaluating our investigational #AngelmanSyndrome (AS) medicine. Read more: $IONS https://ir.ionis.com/news-releases/news-release-details/first-patient-dosed-pivotal-phase-3-reveal-clinical-study-ion582 https://ir.ionis.com/news-releases/news-release-details/first-patient-dosed-pivotal-phase-3-reveal-clinical-study-ion582"
X Link 2025-06-11T11:02Z [----] followers, [---] engagements

"Today with @Biogen we shared positive interim results from the Phase [--] study of our investigational ASO for the potential treatment of spinal muscular atrophy (#SMA). Read more: $IONS https://ir.ionis.com/news-releases/news-release-details/ionis-announces-biogen-advance-salanersen-sma-registrational https://ir.ionis.com/news-releases/news-release-details/ionis-announces-biogen-advance-salanersen-sma-registrational"
X Link 2025-06-25T11:32Z [----] followers, [----] engagements

"Save the date for our Q2 [----] earnings webcast. Register now and tune in live on July [--] at 11:30 am ET: $IONS https://ir.ionis.com/news-releases/news-release-details/ionis-hold-second-quarter-2025-financial-results-webcast https://ir.ionis.com/news-releases/news-release-details/ionis-hold-second-quarter-2025-financial-results-webcast"
X Link 2025-07-17T20:17Z [----] followers, [---] engagements

"Were proud to share that @AAAAI_org Journal of Allergy and Clinical Immunology (JACI) In Practice today published the Phase [--] results for our investigational medicine for the treatment of hereditary angioedema (#HAE). Learn more: $IONS https://ir.ionis.com/news-releases/news-release-details/phase-3-oasisplus-data-demonstrating-benefit-donidalorsen-hae https://ir.ionis.com/news-releases/news-release-details/phase-3-oasisplus-data-demonstrating-benefit-donidalorsen-hae"
X Link 2025-07-21T11:02Z [----] followers, [---] engagements

"Today the CHMP in the European Union recommended the approval of Ionis and Sobis treatment for familial chylomicronemia syndrome (FCS). Read more about the news: $IONS https://ir.ionis.com/news-releases/news-release-details/tryngolzar-olezarsen-recommended-approval-eu-chmp-familial https://ir.ionis.com/news-releases/news-release-details/tryngolzar-olezarsen-recommended-approval-eu-chmp-familial"
X Link 2025-07-25T11:17Z [----] followers, [----] engagements

"Today we reported Q2 [----] financial results. Read more about our updates and tune in live to the webcast today at 11:30 AM ET to hear our second quarter highlights: $IONS https://ir.ionis.com/news-releases/news-release-details/ionis-reports-second-quarter-2025-financial-results-and https://ir.ionis.com/news-releases/news-release-details/ionis-reports-second-quarter-2025-financial-results-and"
X Link 2025-07-30T11:01Z [----] followers, [----] engagements

"Were proud to share that our medicine for familial chylomicronemia syndrome (FCS) has been nominated for the #PrixGalien USA Award for Best Product for Rare/Orphan Diseases Thank you @GalienFdn #PrixGalien #LivingwithFCS #RareDisease https://www.prnewswire.com/news-releases/the-galien-foundation-announces-2025-prix-galien-usa-nominees-for-best-biotechnology-product-best-pharmaceutical-product-and-best-product-for-rareorphan-diseases-302526561.htmltc=eml_cleartime"
X Link 2025-08-11T21:16Z [----] followers, [----] engagements

"BREAKING NEWS: Were excited to share we have received U.S. FDA approval for DAWNZERA (donidalorsen) evidence of our dedication to turning groundbreaking science and technology into innovative medicines. Read more: $IONS https://ir.ionis.com/news-releases/news-release-details/dawnzeratm-donidalorsen-approved-us-first-and-only-rna-targeted https://ir.ionis.com/news-releases/news-release-details/dawnzeratm-donidalorsen-approved-us-first-and-only-rna-targeted"
X Link 2025-08-21T15:47Z [----] followers, [----] engagements

"Ionis will host an investor webcast to discuss the U.S. FDA approval of our medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients age [--] and older. Read more and access a link to the webcast here: $IONS https://app.webinar.net/ALp3J3VBrOv https://app.webinar.net/ALp3J3VBrOv"
X Link 2025-08-21T15:52Z [----] followers, [---] engagements

"Today the U.S. FDA approved our medicine for hereditary angioedema (#HAE) marking a significant and encouraging advance for the community many of whom continue to live with unpredictable severe swelling attacks. Hear from our CEO Brett P. Monia PhD"
X Link 2025-08-21T17:09Z [----] followers, [----] engagements

"Living with hereditary angioedema (#HAE) looks different for everyone but many continue to face unpredictable & debilitating attacks. Were honored to support the HAE community through our long-standing partnership with @US_HAEA & proud to now provide a new treatment option"
X Link 2025-08-26T14:30Z [----] followers, [---] engagements

"Today we announced positive topline results from our Phase [--] studies for severe hypertriglyceridemia (sHTG) defined by triglycerides [---] mg/dL and characterized by an increased risk of acute pancreatitis and other morbidities. $IONS https://ir.ionis.com/news-releases/news-release-details/olezarsen-significantly-reduces-triglycerides-and-acute https://ir.ionis.com/news-releases/news-release-details/olezarsen-significantly-reduces-triglycerides-and-acute"
X Link 2025-09-02T11:01Z [----] followers, 10.9K engagements

"Today $IONS will host an investor webcast to discuss the Phase [--] topline results for our treatment for severe hypertriglyceridemia (sHTG). Access a link to the webcast here: https://app.webinar.net/0rdExgNLJVq https://app.webinar.net/0rdExgNLJVq"
X Link 2025-09-02T11:05Z [----] followers, [----] engagements

"Today we announced positive topline results from our Phase [--] studies for severe hypertriglyceridemia (sHTG). The data mark a major step forward in delivering transformative care to people in need with sHTG. Read more: https://ir.ionis.com/news-releases/news-release-details/olezarsen-significantly-reduces-triglycerides-and-acute https://ir.ionis.com/news-releases/news-release-details/olezarsen-significantly-reduces-triglycerides-and-acute"
X Link 2025-09-02T19:47Z [----] followers, [---] engagements

"Today we announced that the U.S. FDA has granted #BreakthroughTherapy designation for our investigational medicine for #AngelmanSyndrome (AS). Read more about the news: $IONS https://ir.ionis.com/news-releases/news-release-details/ionis-receives-us-fda-breakthrough-therapy-designation-ion582 https://ir.ionis.com/news-releases/news-release-details/ionis-receives-us-fda-breakthrough-therapy-designation-ion582"
X Link 2025-09-09T11:02Z [----] followers, [----] engagements

"Our medicine for hereditary angioedema (#HAE) is now approved and available to patients in the U.S. bringing a new approach to treating this #raredisease. HCPs: Hear from Dr. William Lumry on the significance of this milestone. Learn more: https://ir.ionis.com/news-releases/news-release-details/dawnzeratm-donidalorsen-approved-us-first-and-only-rna-targeted https://ir.ionis.com/news-releases/news-release-details/dawnzeratm-donidalorsen-approved-us-first-and-only-rna-targeted"
X Link 2025-09-10T18:30Z [----] followers, [---] engagements

"Today with our partners at Adapt Functional Movement Center & @CAFoundation we celebrate the 10th anniversary of #SurfAway+ an inclusive adaptive event for rare #neurological disease communities. Read how our event has evolved over the last decade: https://ir.ionis.com/news-releases/news-release-details/ionis-expands-surf-away-event-marking-10-years-creating-unique https://ir.ionis.com/news-releases/news-release-details/ionis-expands-surf-away-event-marking-10-years-creating-unique"
X Link 2025-09-12T11:06Z [----] followers, [----] engagements

"Akcea Therapeutics Announces Closing of Initial Public Offering http://phx.corporate-ir.net/phoenix.zhtmlc=222170&p=RssLanding&cat=news&id=2287468 http://phx.corporate-ir.net/phoenix.zhtmlc=222170&p=RssLanding&cat=news&id=2287468"
X Link 2017-07-19T20:18Z [----] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing